184 related articles for article (PubMed ID: 34120271)
1. ApoE4-positive multiple sclerosis patients are more likely to have cognitive impairment: a cross-sectional study.
Mashayekhi F; Sadigh-Eteghad S; Naseri A; Asadi M; Abbasi Garravnd N; Talebi M
Neurol Sci; 2022 Feb; 43(2):1189-1196. PubMed ID: 34120271
[TBL] [Abstract][Full Text] [Related]
2. The association of apolipoprotein E (ApoE) genotype and cognitive outcomes in multiple sclerosis; a systematic review and meta-analysis.
Naseri A; Baghernezhad K; Seyedi-Sahebari S; Alhoseini SA; Gholipour-Khalili E; Zafarani F; Talebi M
Mult Scler Relat Disord; 2022 Sep; 65():104011. PubMed ID: 35803087
[TBL] [Abstract][Full Text] [Related]
3. Brief international cognitive assessment for multiple sclerosis (BICAMS): A danish validation study of sensitivity in early stages of MS.
Marstrand L; Østerberg O; Walsted T; Skov AC; Schreiber KI; Sellebjerg F
Mult Scler Relat Disord; 2020 Jan; 37():101458. PubMed ID: 31683230
[TBL] [Abstract][Full Text] [Related]
4. Validation of the French version of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS).
Maubeuge N; Deloire MSA; Brochet B; Ehrlé N; Charré-Morin J; Saubusse A; Ruet A;
Mult Scler Relat Disord; 2021 Feb; 48():102692. PubMed ID: 33352358
[TBL] [Abstract][Full Text] [Related]
5. The Norwegian translation of the brief international cognitive assessment for multiple sclerosis (BICAMS).
Skorve E; Lundervold AJ; Torkildsen Ø; Myhr KM
Mult Scler Relat Disord; 2019 Nov; 36():101408. PubMed ID: 31610403
[TBL] [Abstract][Full Text] [Related]
6. The Italian validation of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) and the application of the Cognitive Impairment Index scoring procedure in MS patients.
Argento O; Incerti CC; Quartuccio ME; Magistrale G; Francia A; Caltagirone C; Pisani V; Nocentini U
Neurol Sci; 2018 Jul; 39(7):1237-1244. PubMed ID: 29704074
[TBL] [Abstract][Full Text] [Related]
7. Serum lipids and cognitive outcomes in multiple sclerosis; a systematic review and meta-analysis.
Sanaie S; Koohi N; Mosaddeghi-Heris R; Rezai S; Movagharnia E; Karimi H; Moghaddamziabari S; Hamzehzadeh S; Gholipour-Khalili E; Talebi M; Naseri A
Mult Scler Relat Disord; 2024 May; 85():105530. PubMed ID: 38522226
[TBL] [Abstract][Full Text] [Related]
8. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
[TBL] [Abstract][Full Text] [Related]
9. A one-year follow-up study of the Symbol Digit Modalities Test (SDMT) and the Paced Auditory Serial Addition Test (PASAT) in relapsing-remitting multiple sclerosis: an appraisal of comparative longitudinal sensitivity.
López-Góngora M; Querol L; Escartín A
BMC Neurol; 2015 Mar; 15():40. PubMed ID: 25886168
[TBL] [Abstract][Full Text] [Related]
10. Thalamic-hippocampal-prefrontal disruption in relapsing-remitting multiple sclerosis.
Kern KC; Gold SM; Lee B; Montag M; Horsfall J; O'Connor MF; Sicotte NL
Neuroimage Clin; 2015; 8():440-7. PubMed ID: 26106524
[TBL] [Abstract][Full Text] [Related]
11. Circulatory antioxidant and oxidative stress markers are in correlation with demographics but not cognitive functions in multiple sclerosis patients.
Naseri A; Forghani N; Sadigh-Eteghad S; Shanehbandi D; Asadi M; Nasiri E; Talebi M
Mult Scler Relat Disord; 2022 Jan; 57():103432. PubMed ID: 34922253
[TBL] [Abstract][Full Text] [Related]
12. A preliminary validation of the brief international cognitive assessment for multiple sclerosis (BICAMS) tool in an Irish population with multiple sclerosis (MS).
O'Connell K; Langdon D; Tubridy N; Hutchinson M; McGuigan C
Mult Scler Relat Disord; 2015 Nov; 4(6):521-5. PubMed ID: 26590658
[TBL] [Abstract][Full Text] [Related]
13. Olfactory function and cognition in relapsing-remitting and secondary-progressive multiple sclerosis.
Carotenuto A; Costabile T; Moccia M; Falco F; Scala MR; Russo CV; Saccà F; De Rosa A; Lanzillo R; Brescia Morra V
Mult Scler Relat Disord; 2019 Jan; 27():1-6. PubMed ID: 30273697
[TBL] [Abstract][Full Text] [Related]
14. Cognitive impairment differs between primary progressive and relapsing-remitting MS.
Ruet A; Deloire M; Charré-Morin J; Hamel D; Brochet B
Neurology; 2013 Apr; 80(16):1501-8. PubMed ID: 23516324
[TBL] [Abstract][Full Text] [Related]
15. The relationship between cognitive function and body mass index in multiple sclerosis patients.
Owji M; Ashraf-Ganjouei A; Sahraian MA; Bidadian M; Ghadiri F; Naser Moghadasi A
Mult Scler Relat Disord; 2019 Jul; 32():37-40. PubMed ID: 31030017
[TBL] [Abstract][Full Text] [Related]
16. The correlation between dyslipidemia and cognitive impairment in multiple sclerosis patients.
Noori H; Gheini MR; Rezaeimanesh N; Saeedi R; Rezaei Aliabadi H; Sahraian MA; Naser Moghadasi A
Mult Scler Relat Disord; 2019 Nov; 36():101415. PubMed ID: 31586799
[TBL] [Abstract][Full Text] [Related]
17. Cognitive performance in relapsing remitting multiple sclerosis: a longitudinal study in daily practice using a brief computerized cognitive battery.
Edgar C; Jongen PJ; Sanders E; Sindic C; Goffette S; Dupuis M; Jacquerye P; Guillaume D; Reznik R; Wesnes K
BMC Neurol; 2011 Jun; 11():68. PubMed ID: 21649910
[TBL] [Abstract][Full Text] [Related]
18. The Cambridge Neuropsychological Test Automated Battery (CANTAB) Versus the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) for the Assessment of Cognitive Function in Patients with Multiple Sclerosis.
Talebi M; Majdi A; Kamari F; Sadigh-Eteghad S
Mult Scler Relat Disord; 2020 Aug; 43():102172. PubMed ID: 32442887
[TBL] [Abstract][Full Text] [Related]
19. A two-year longitudinal follow-up of cognitive performance assessed by BICAMS in newly diagnosed patients with MS.
Skorve E; Lundervold AJ; Torkildsen Ø; Myhr KM
Mult Scler Relat Disord; 2020 Nov; 46():102577. PubMed ID: 33296975
[TBL] [Abstract][Full Text] [Related]
20. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
